RO7790121: RO7790121/Placebo will be administered as IV infusion. RO7790121/Placebo will be administered as SC injection.

2 trials

Sponsors

Kun Tae Park

Conditions

Moderately to Severely Active Crohn's DisesaseUlcerative Colitis

Phase 3

A Study to Assess the Efficacy and Safety of RO7790121 for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis

Active, not recruitingJPRN-jRCT2041240200

Kun Tae ParkUlcerative Colitis

Start: 2025-04-18Target: 400Updated: 2026-05-25

A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With RO7790121 in Patients With Moderately to Severely Active Crohn's Disease

RecruitingJPRN-jRCT2041250054

Kun Tae ParkModerately to Severely Active Crohn's Disesase

Start: 2025-09-04Target: 600Updated: 2026-06-29